Fingolimod hydrochloride

Suppliers

Names

[ Name ]:
Fingolimod hydrochloride

[Synonym ]:
FTY720 Hydrochloride
2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride
2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (1:1)
FTY720
2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiolhydrochlorid
2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride
Fingolimod Hydrochloride
2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride (1:1)
2-Amino-2-[2-(4-n-octylphenyl)ethyl]propane-1,3-diol Hydrochloride
2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride
1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, hydrochloride (1:1)
Fingolimod HCl
2-Amino-2-[2-(4-octylphényl)éthyl]-1,3-propanediol chlorhydrate
2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol hydrochloride Fingolimod hydrochloride
2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride
MFCD00939512
Fingolimod (hydrochloride)

Chemical & Physical Properties

[ Density]:
1.016g/cm3

[ Boiling Point ]:
479.5ºC at 760 mmHg

[ Melting Point ]:
102-107ºC

[ Molecular Formula ]:
C₁₉H₃₄ClNO₂

[ Molecular Weight ]:
343.932

[ Flash Point ]:
243.8ºC

[ Exact Mass ]:
343.227814

[ PSA ]:
66.48000

[ LogP ]:
4.70660

[ Vapour Pressure ]:
5.28E-10mmHg at 25°C

[ Index of Refraction ]:
1.531

[ Storage condition ]:
-20°C Freezer

MSDS

Click to get detail MSDS

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335-H412

[ Precautionary Statements ]:
P261-P273-P305 + P351 + P338

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38-52/53

[ Safety Phrases ]:
26-61

[ RIDADR ]:
NONH for all modes of transport

[ HS Code ]:
2922199090

Customs

[ HS Code ]: 2922199090

[ Summary ]:
2922199090. other amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

Articles

Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug.

JAMA Neurol. 72(1) , 10-3, (2015)

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

JAMA Neurol. 72(1) , 31-9, (2015)

Varicella-zoster virus (VZV) infections increasingly are reported in patients with multiple sclerosis (MS) and constitute an area of significant concern, especially with the advent of more disease-mod...

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.

Neurology 83(23) , 2153-7, (2014)

To assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (BMI) affects the risk of fingolimod-induced lymphopenia in patients with relapsing-remittin...